nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—MAP3K7—prostate cancer	0.118	0.311	CbGaD
Sorafenib—RALBP1—prostate cancer	0.1	0.264	CbGaD
Sorafenib—PDGFRB—prostate cancer	0.059	0.156	CbGaD
Sorafenib—KDR—prostate cancer	0.0447	0.118	CbGaD
Sorafenib—CYP3A5—prostate cancer	0.027	0.0713	CbGaD
Sorafenib—RALBP1—Doxorubicin—prostate cancer	0.0247	0.0761	CbGbCtD
Sorafenib—CYP2C19—prostate cancer	0.0184	0.0485	CbGaD
Sorafenib—CYP3A4—prostate cancer	0.0117	0.0309	CbGaD
Sorafenib—ABCC4—Conjugated Estrogens—prostate cancer	0.0111	0.0343	CbGbCtD
Sorafenib—UGT1A1—Estradiol—prostate cancer	0.00957	0.0295	CbGbCtD
Sorafenib—ABCG2—Cabazitaxel—prostate cancer	0.00937	0.0289	CbGbCtD
Sorafenib—ABCG2—Estrone—prostate cancer	0.00916	0.0282	CbGbCtD
Sorafenib—ABCC2—Ethinyl Estradiol—prostate cancer	0.00903	0.0278	CbGbCtD
Sorafenib—CYP2C8—Nilutamide—prostate cancer	0.00815	0.0251	CbGbCtD
Sorafenib—CYP3A5—Flutamide—prostate cancer	0.00702	0.0216	CbGbCtD
Sorafenib—CYP2C19—Nilutamide—prostate cancer	0.00683	0.021	CbGbCtD
Sorafenib—CYP2C19—Bicalutamide—prostate cancer	0.00683	0.021	CbGbCtD
Sorafenib—CYP2C8—Abiraterone—prostate cancer	0.00675	0.0208	CbGbCtD
Sorafenib—ABCC2—Conjugated Estrogens—prostate cancer	0.00663	0.0204	CbGbCtD
Sorafenib—CYP2B6—Estrone—prostate cancer	0.00644	0.0198	CbGbCtD
Sorafenib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.00629	0.0194	CbGbCtD
Sorafenib—UGT1A1—Etoposide—prostate cancer	0.00625	0.0192	CbGbCtD
Sorafenib—ABCG2—Conjugated Estrogens—prostate cancer	0.00599	0.0185	CbGbCtD
Sorafenib—CYP2B6—Ethinyl Estradiol—prostate cancer	0.00574	0.0177	CbGbCtD
Sorafenib—CYP2C9—Bicalutamide—prostate cancer	0.00568	0.0175	CbGbCtD
Sorafenib—CYP2C9—Nilutamide—prostate cancer	0.00568	0.0175	CbGbCtD
Sorafenib—CYP2C19—Flutamide—prostate cancer	0.00566	0.0174	CbGbCtD
Sorafenib—ABCG2—Mitoxantrone—prostate cancer	0.00545	0.0168	CbGbCtD
Sorafenib—ABCG2—Estradiol—prostate cancer	0.00526	0.0162	CbGbCtD
Sorafenib—CYP1A2—Flutamide—prostate cancer	0.00522	0.0161	CbGbCtD
Sorafenib—CYP2D6—Bicalutamide—prostate cancer	0.0052	0.016	CbGbCtD
Sorafenib—CYP3A5—Cabazitaxel—prostate cancer	0.00519	0.016	CbGbCtD
Sorafenib—ABCB1—Estramustine—prostate cancer	0.00513	0.0158	CbGbCtD
Sorafenib—CYP3A5—Estrone—prostate cancer	0.00508	0.0156	CbGbCtD
Sorafenib—CYP2C8—Cabazitaxel—prostate cancer	0.00499	0.0154	CbGbCtD
Sorafenib—CYP2C8—Ethinyl Estradiol—prostate cancer	0.00435	0.0134	CbGbCtD
Sorafenib—CYP2D6—Abiraterone—prostate cancer	0.00431	0.0133	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Estradiol—prostate cancer	0.00389	0.012	CbGbCtD
Sorafenib—CYP3A7—Estradiol—prostate cancer	0.00389	0.012	CbGbCtD
Sorafenib—ABCC2—Etoposide—prostate cancer	0.0038	0.0117	CbGbCtD
Sorafenib—CYP1A2—Estrone—prostate cancer	0.00378	0.0116	CbGbCtD
Sorafenib—ABCC2—Docetaxel—prostate cancer	0.00348	0.0107	CbGbCtD
Sorafenib—ABCG2—Etoposide—prostate cancer	0.00344	0.0106	CbGbCtD
Sorafenib—CYP2C9—Estrone—prostate cancer	0.0034	0.0105	CbGbCtD
Sorafenib—ABCB1—Cabazitaxel—prostate cancer	0.00338	0.0104	CbGbCtD
Sorafenib—CYP3A4—Bicalutamide—prostate cancer	0.0033	0.0102	CbGbCtD
Sorafenib—ABCB1—Estrone—prostate cancer	0.0033	0.0102	CbGbCtD
Sorafenib—ABCG2—Docetaxel—prostate cancer	0.00314	0.00968	CbGbCtD
Sorafenib—CYP3A4—Estramustine—prostate cancer	0.00307	0.00946	CbGbCtD
Sorafenib—ABCB1—Ethinyl Estradiol—prostate cancer	0.00294	0.00907	CbGbCtD
Sorafenib—CYP3A5—Estradiol—prostate cancer	0.00292	0.00898	CbGbCtD
Sorafenib—CYP2C8—Estradiol—prostate cancer	0.0028	0.00863	CbGbCtD
Sorafenib—CYP3A4—Flutamide—prostate cancer	0.00274	0.00843	CbGbCtD
Sorafenib—CYP3A4—Abiraterone—prostate cancer	0.00274	0.00843	CbGbCtD
Sorafenib—ABCC2—Doxorubicin—prostate cancer	0.00259	0.00798	CbGbCtD
Sorafenib—CYP2C9—Capecitabine—prostate cancer	0.00258	0.00794	CbGbCtD
Sorafenib—CYP1A2—Conjugated Estrogens—prostate cancer	0.00247	0.00761	CbGbCtD
Sorafenib—CYP2C19—Estradiol—prostate cancer	0.00235	0.00724	CbGbCtD
Sorafenib—ABCG2—Doxorubicin—prostate cancer	0.00234	0.00722	CbGbCtD
Sorafenib—CYP3A7—Docetaxel—prostate cancer	0.00232	0.00715	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Docetaxel—prostate cancer	0.00232	0.00715	CbGbCtD
Sorafenib—CYP1A2—Estradiol—prostate cancer	0.00217	0.00668	CbGbCtD
Sorafenib—ABCB1—Conjugated Estrogens—prostate cancer	0.00216	0.00665	CbGbCtD
Sorafenib—CYP3A4—Cabazitaxel—prostate cancer	0.00202	0.00624	CbGbCtD
Sorafenib—CYP2C19—Prednisone—prostate cancer	0.00202	0.00623	CbGbCtD
Sorafenib—CYP3A4—Estrone—prostate cancer	0.00198	0.00609	CbGbCtD
Sorafenib—ABCB1—Mitoxantrone—prostate cancer	0.00196	0.00605	CbGbCtD
Sorafenib—CYP2C9—Estradiol—prostate cancer	0.00195	0.00602	CbGbCtD
Sorafenib—CYP3A5—Etoposide—prostate cancer	0.0019	0.00586	CbGbCtD
Sorafenib—ABCB1—Estradiol—prostate cancer	0.0019	0.00584	CbGbCtD
Sorafenib—CYP2C8—Etoposide—prostate cancer	0.00183	0.00564	CbGbCtD
Sorafenib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00176	0.00543	CbGbCtD
Sorafenib—CYP3A5—Docetaxel—prostate cancer	0.00174	0.00536	CbGbCtD
Sorafenib—PDGFRA—penis—prostate cancer	0.00169	0.0283	CbGeAlD
Sorafenib—CYP2B6—Doxorubicin—prostate cancer	0.00165	0.00507	CbGbCtD
Sorafenib—ABCB1—Prednisone—prostate cancer	0.00163	0.00502	CbGbCtD
Sorafenib—CYP1A2—Etoposide—prostate cancer	0.00142	0.00436	CbGbCtD
Sorafenib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00129	0.00399	CbGbCtD
Sorafenib—ABCB1—Etoposide—prostate cancer	0.00124	0.00381	CbGbCtD
Sorafenib—CYP3A4—Mitoxantrone—prostate cancer	0.00118	0.00362	CbGbCtD
Sorafenib—CYP3A4—Estradiol—prostate cancer	0.00114	0.0035	CbGbCtD
Sorafenib—ABCB1—Docetaxel—prostate cancer	0.00113	0.00349	CbGbCtD
Sorafenib—UGT1A1—urine—prostate cancer	0.00107	0.018	CbGeAlD
Sorafenib—CYP3A4—Prednisone—prostate cancer	0.000977	0.00301	CbGbCtD
Sorafenib—Regorafenib—FGFR2—prostate cancer	0.000923	0.322	CrCbGaD
Sorafenib—MUSK—testis—prostate cancer	0.000872	0.0146	CbGeAlD
Sorafenib—MAPK11—prostate gland—prostate cancer	0.000861	0.0144	CbGeAlD
Sorafenib—CDK7—prostate gland—prostate cancer	0.000847	0.0142	CbGeAlD
Sorafenib—ABCB1—Doxorubicin—prostate cancer	0.000845	0.0026	CbGbCtD
Sorafenib—TAOK2—prostate gland—prostate cancer	0.000841	0.0141	CbGeAlD
Sorafenib—CYP2D6—Doxorubicin—prostate cancer	0.000796	0.00245	CbGbCtD
Sorafenib—CDKL3—testis—prostate cancer	0.000777	0.013	CbGeAlD
Sorafenib—EPHA6—prostate gland—prostate cancer	0.000773	0.0129	CbGeAlD
Sorafenib—CYP3A4—Etoposide—prostate cancer	0.000742	0.00229	CbGbCtD
Sorafenib—ZAK—prostate gland—prostate cancer	0.000732	0.0123	CbGeAlD
Sorafenib—Regorafenib—PDGFRB—prostate cancer	0.00073	0.254	CrCbGaD
Sorafenib—HIPK3—prostate gland—prostate cancer	0.000717	0.012	CbGeAlD
Sorafenib—CDKL2—testis—prostate cancer	0.000711	0.0119	CbGeAlD
Sorafenib—CYP3A4—Docetaxel—prostate cancer	0.000679	0.00209	CbGbCtD
Sorafenib—TIE1—prostate gland—prostate cancer	0.00067	0.0112	CbGeAlD
Sorafenib—BRAF—prostate gland—prostate cancer	0.000642	0.0108	CbGeAlD
Sorafenib—MAPK15—testis—prostate cancer	0.00064	0.0107	CbGeAlD
Sorafenib—ZAK—seminal vesicle—prostate cancer	0.000619	0.0104	CbGeAlD
Sorafenib—EPHX2—prostate gland—prostate cancer	0.000614	0.0103	CbGeAlD
Sorafenib—CYP2C19—urine—prostate cancer	0.000581	0.00973	CbGeAlD
Sorafenib—CDK7—renal system—prostate cancer	0.000578	0.00968	CbGeAlD
Sorafenib—TAOK2—urethra—prostate cancer	0.000563	0.00943	CbGeAlD
Sorafenib—FLT4—prostate gland—prostate cancer	0.000554	0.00927	CbGeAlD
Sorafenib—Regorafenib—KDR—prostate cancer	0.000553	0.193	CrCbGaD
Sorafenib—FGFR1—prostate gland—prostate cancer	0.000546	0.00915	CbGeAlD
Sorafenib—EPHX2—seminal vesicle—prostate cancer	0.000519	0.0087	CbGeAlD
Sorafenib—MAP3K7—prostate gland—prostate cancer	0.000517	0.00866	CbGeAlD
Sorafenib—CYP3A4—Doxorubicin—prostate cancer	0.000506	0.00156	CbGbCtD
Sorafenib—MKNK2—prostate gland—prostate cancer	0.000501	0.0084	CbGeAlD
Sorafenib—MKNK1—prostate gland—prostate cancer	0.000495	0.00829	CbGeAlD
Sorafenib—TIE1—epithelium—prostate cancer	0.000492	0.00825	CbGeAlD
Sorafenib—ZAK—urethra—prostate cancer	0.00049	0.00822	CbGeAlD
Sorafenib—RET—prostate gland—prostate cancer	0.000489	0.00819	CbGeAlD
Sorafenib—HIPK3—renal system—prostate cancer	0.000488	0.00819	CbGeAlD
Sorafenib—CYP1A2—urine—prostate cancer	0.000474	0.00795	CbGeAlD
Sorafenib—RALBP1—prostate gland—prostate cancer	0.000452	0.00758	CbGeAlD
Sorafenib—CYP2C9—urine—prostate cancer	0.00045	0.00755	CbGeAlD
Sorafenib—TIE1—urethra—prostate cancer	0.000448	0.00751	CbGeAlD
Sorafenib—MAP3K7—seminal vesicle—prostate cancer	0.000437	0.00733	CbGeAlD
Sorafenib—HIPK4—testis—prostate cancer	0.000431	0.00721	CbGeAlD
Sorafenib—FLT1—prostate gland—prostate cancer	0.00043	0.00721	CbGeAlD
Sorafenib—RAF1—prostate gland—prostate cancer	0.000428	0.00717	CbGeAlD
Sorafenib—EPHB6—prostate gland—prostate cancer	0.000425	0.00713	CbGeAlD
Sorafenib—MKNK2—seminal vesicle—prostate cancer	0.000424	0.0071	CbGeAlD
Sorafenib—EPHX2—urethra—prostate cancer	0.000411	0.00689	CbGeAlD
Sorafenib—STK10—prostate gland—prostate cancer	0.000407	0.00683	CbGeAlD
Sorafenib—FLT4—epithelium—prostate cancer	0.000407	0.00682	CbGeAlD
Sorafenib—PDGFRA—prostate gland—prostate cancer	0.000403	0.00676	CbGeAlD
Sorafenib—UGT1A1—prostate gland—prostate cancer	0.000385	0.00645	CbGeAlD
Sorafenib—RALBP1—seminal vesicle—prostate cancer	0.000383	0.00641	CbGeAlD
Sorafenib—UGT1A9—renal system—prostate cancer	0.000383	0.00641	CbGeAlD
Sorafenib—MAPK11—testis—prostate cancer	0.000379	0.00636	CbGeAlD
Sorafenib—CDK7—testis—prostate cancer	0.000373	0.00626	CbGeAlD
Sorafenib—TAOK2—testis—prostate cancer	0.00037	0.00621	CbGeAlD
Sorafenib—HIPK3—bone marrow—prostate cancer	0.000369	0.00619	CbGeAlD
Sorafenib—MKNK2—epithelium—prostate cancer	0.000368	0.00617	CbGeAlD
Sorafenib—AURKC—testis—prostate cancer	0.000367	0.00616	CbGeAlD
Sorafenib—FGFR1—urethra—prostate cancer	0.000366	0.00613	CbGeAlD
Sorafenib—FLT1—seminal vesicle—prostate cancer	0.000364	0.0061	CbGeAlD
Sorafenib—MAP2K5—prostate gland—prostate cancer	0.000364	0.0061	CbGeAlD
Sorafenib—KDR—prostate gland—prostate cancer	0.000364	0.0061	CbGeAlD
Sorafenib—RAF1—seminal vesicle—prostate cancer	0.000362	0.00606	CbGeAlD
Sorafenib—EPHB6—seminal vesicle—prostate cancer	0.00036	0.00603	CbGeAlD
Sorafenib—RET—epithelium—prostate cancer	0.000359	0.00602	CbGeAlD
Sorafenib—CSF1R—prostate gland—prostate cancer	0.000355	0.00595	CbGeAlD
Sorafenib—MKNK1—Estradiol—Estradiol valerate/Dienogest—prostate cancer	0.000351	0.178	CbGdCrCtD
Sorafenib—MAP3K7—urethra—prostate cancer	0.000346	0.0058	CbGeAlD
Sorafenib—CYP3A4—urine—prostate cancer	0.000343	0.00575	CbGeAlD
Sorafenib—MKNK2—renal system—prostate cancer	0.000341	0.00572	CbGeAlD
Sorafenib—EPHA6—testis—prostate cancer	0.00034	0.0057	CbGeAlD
Sorafenib—CYP2D6—urine—prostate cancer	0.000338	0.00566	CbGeAlD
Sorafenib—MKNK2—urethra—prostate cancer	0.000335	0.00562	CbGeAlD
Sorafenib—RET—renal system—prostate cancer	0.000333	0.00558	CbGeAlD
Sorafenib—MKNK1—urethra—prostate cancer	0.000331	0.00555	CbGeAlD
Sorafenib—BRAF—bone marrow—prostate cancer	0.000331	0.00555	CbGeAlD
Sorafenib—ZAK—testis—prostate cancer	0.000323	0.00541	CbGeAlD
Sorafenib—KIT—prostate gland—prostate cancer	0.000322	0.0054	CbGeAlD
Sorafenib—FLT1—epithelium—prostate cancer	0.000316	0.0053	CbGeAlD
Sorafenib—HIPK3—testis—prostate cancer	0.000316	0.00529	CbGeAlD
Sorafenib—PDGFRB—prostate gland—prostate cancer	0.000315	0.00528	CbGeAlD
Sorafenib—RAF1—epithelium—prostate cancer	0.000314	0.00527	CbGeAlD
Sorafenib—FLT3—bone marrow—prostate cancer	0.000314	0.00526	CbGeAlD
Sorafenib—MAP3K19—testis—prostate cancer	0.000309	0.00518	CbGeAlD
Sorafenib—RALBP1—renal system—prostate cancer	0.000308	0.00517	CbGeAlD
Sorafenib—KDR—seminal vesicle—prostate cancer	0.000308	0.00516	CbGeAlD
Sorafenib—MAP2K5—seminal vesicle—prostate cancer	0.000308	0.00516	CbGeAlD
Sorafenib—RALBP1—urethra—prostate cancer	0.000303	0.00508	CbGeAlD
Sorafenib—CSF1R—seminal vesicle—prostate cancer	0.0003	0.00503	CbGeAlD
Sorafenib—MKNK1—Estradiol—Estramustine—prostate cancer	0.000299	0.151	CbGdCrCtD
Sorafenib—TIE1—testis—prostate cancer	0.000295	0.00494	CbGeAlD
Sorafenib—FLT1—renal system—prostate cancer	0.000293	0.00492	CbGeAlD
Sorafenib—RAF1—renal system—prostate cancer	0.000292	0.00489	CbGeAlD
Sorafenib—FLT1—urethra—prostate cancer	0.000288	0.00483	CbGeAlD
Sorafenib—RAF1—urethra—prostate cancer	0.000286	0.0048	CbGeAlD
Sorafenib—FLT4—bone marrow—prostate cancer	0.000285	0.00478	CbGeAlD
Sorafenib—EPHB6—urethra—prostate cancer	0.000285	0.00477	CbGeAlD
Sorafenib—BRAF—testis—prostate cancer	0.000283	0.00474	CbGeAlD
Sorafenib—STK10—renal system—prostate cancer	0.000278	0.00465	CbGeAlD
Sorafenib—MAPK11—lymph node—prostate cancer	0.000275	0.00461	CbGeAlD
Sorafenib—PDGFRA—renal system—prostate cancer	0.000275	0.00461	CbGeAlD
Sorafenib—KIT—seminal vesicle—prostate cancer	0.000273	0.00457	CbGeAlD
Sorafenib—CDK7—lymph node—prostate cancer	0.000271	0.00453	CbGeAlD
Sorafenib—EPHX2—testis—prostate cancer	0.00027	0.00453	CbGeAlD
Sorafenib—FLT3—testis—prostate cancer	0.000268	0.0045	CbGeAlD
Sorafenib—TAOK2—lymph node—prostate cancer	0.000268	0.0045	CbGeAlD
Sorafenib—KDR—epithelium—prostate cancer	0.000267	0.00448	CbGeAlD
Sorafenib—MAP3K7—bone marrow—prostate cancer	0.000266	0.00446	CbGeAlD
Sorafenib—AURKC—lymph node—prostate cancer	0.000266	0.00446	CbGeAlD
Sorafenib—PDGFRB—seminal vesicle—prostate cancer	0.000266	0.00446	CbGeAlD
Sorafenib—UGT1A1—renal system—prostate cancer	0.000262	0.00439	CbGeAlD
Sorafenib—MKNK2—bone marrow—prostate cancer	0.000258	0.00433	CbGeAlD
Sorafenib—MKNK1—bone marrow—prostate cancer	0.000255	0.00427	CbGeAlD
Sorafenib—ABCC4—prostate gland—prostate cancer	0.000251	0.0042	CbGeAlD
Sorafenib—KDR—renal system—prostate cancer	0.000248	0.00415	CbGeAlD
Sorafenib—FLT4—testis—prostate cancer	0.000244	0.00409	CbGeAlD
Sorafenib—KDR—urethra—prostate cancer	0.000244	0.00408	CbGeAlD
Sorafenib—MAP2K5—urethra—prostate cancer	0.000244	0.00408	CbGeAlD
Sorafenib—ABCC2—prostate gland—prostate cancer	0.000243	0.00407	CbGeAlD
Sorafenib—FGFR1—testis—prostate cancer	0.000241	0.00403	CbGeAlD
Sorafenib—CSF1R—urethra—prostate cancer	0.000238	0.00398	CbGeAlD
Sorafenib—MKNK1—Estradiol—Estrone—prostate cancer	0.000237	0.12	CbGdCrCtD
Sorafenib—KIT—epithelium—prostate cancer	0.000237	0.00397	CbGeAlD
Sorafenib—ZAK—lymph node—prostate cancer	0.000234	0.00392	CbGeAlD
Sorafenib—RALBP1—bone marrow—prostate cancer	0.000233	0.00391	CbGeAlD
Sorafenib—PDGFRB—epithelium—prostate cancer	0.000231	0.00388	CbGeAlD
Sorafenib—HIPK3—lymph node—prostate cancer	0.000229	0.00383	CbGeAlD
Sorafenib—MAP3K7—testis—prostate cancer	0.000228	0.00382	CbGeAlD
Sorafenib—Regorafenib—CYP2C19—prostate cancer	0.000227	0.0791	CrCbGaD
Sorafenib—MKNK2—testis—prostate cancer	0.000221	0.0037	CbGeAlD
Sorafenib—RAF1—bone marrow—prostate cancer	0.00022	0.00369	CbGeAlD
Sorafenib—KIT—renal system—prostate cancer	0.00022	0.00368	CbGeAlD
Sorafenib—MKNK1—testis—prostate cancer	0.000218	0.00365	CbGeAlD
Sorafenib—KIT—urethra—prostate cancer	0.000216	0.00362	CbGeAlD
Sorafenib—RET—testis—prostate cancer	0.000215	0.00361	CbGeAlD
Sorafenib—PDGFRB—renal system—prostate cancer	0.000215	0.0036	CbGeAlD
Sorafenib—TIE1—lymph node—prostate cancer	0.000214	0.00358	CbGeAlD
Sorafenib—PDGFRB—urethra—prostate cancer	0.000211	0.00353	CbGeAlD
Sorafenib—STK10—bone marrow—prostate cancer	0.00021	0.00352	CbGeAlD
Sorafenib—MKNK1—Estradiol—Conjugated Estrogens—prostate cancer	0.000209	0.106	CbGdCrCtD
Sorafenib—BRAF—lymph node—prostate cancer	0.000205	0.00344	CbGeAlD
Sorafenib—RALBP1—testis—prostate cancer	0.000199	0.00334	CbGeAlD
Sorafenib—EPHX2—lymph node—prostate cancer	0.000196	0.00328	CbGeAlD
Sorafenib—FLT3—lymph node—prostate cancer	0.000195	0.00326	CbGeAlD
Sorafenib—FLT1—testis—prostate cancer	0.00019	0.00318	CbGeAlD
Sorafenib—RAF1—testis—prostate cancer	0.000188	0.00316	CbGeAlD
Sorafenib—KDR—bone marrow—prostate cancer	0.000187	0.00314	CbGeAlD
Sorafenib—EPHB6—testis—prostate cancer	0.000187	0.00314	CbGeAlD
Sorafenib—CSF1R—bone marrow—prostate cancer	0.000183	0.00307	CbGeAlD
Sorafenib—Vismodegib—CYP2C19—prostate cancer	0.00018	0.0627	CrCbGaD
Sorafenib—STK10—testis—prostate cancer	0.000179	0.00301	CbGeAlD
Sorafenib—PDGFRA—testis—prostate cancer	0.000178	0.00298	CbGeAlD
Sorafenib—ABCG2—prostate gland—prostate cancer	0.000177	0.00297	CbGeAlD
Sorafenib—FLT4—lymph node—prostate cancer	0.000177	0.00296	CbGeAlD
Sorafenib—MKNK1—Estradiol—Ethinyl Estradiol—prostate cancer	0.000176	0.0888	CbGdCrCtD
Sorafenib—FGFR1—lymph node—prostate cancer	0.000174	0.00292	CbGeAlD
Sorafenib—ABCC4—renal system—prostate cancer	0.000171	0.00286	CbGeAlD
Sorafenib—KIT—bone marrow—prostate cancer	0.000166	0.00278	CbGeAlD
Sorafenib—ABCC2—renal system—prostate cancer	0.000165	0.00277	CbGeAlD
Sorafenib—MAP3K7—lymph node—prostate cancer	0.000165	0.00277	CbGeAlD
Sorafenib—CYP3A5—prostate gland—prostate cancer	0.000164	0.00275	CbGeAlD
Sorafenib—PDGFRB—bone marrow—prostate cancer	0.000162	0.00272	CbGeAlD
Sorafenib—KDR—testis—prostate cancer	0.00016	0.00269	CbGeAlD
Sorafenib—MAP2K5—testis—prostate cancer	0.00016	0.00269	CbGeAlD
Sorafenib—MKNK2—lymph node—prostate cancer	0.00016	0.00268	CbGeAlD
Sorafenib—MKNK1—lymph node—prostate cancer	0.000158	0.00265	CbGeAlD
Sorafenib—CSF1R—testis—prostate cancer	0.000156	0.00262	CbGeAlD
Sorafenib—RET—lymph node—prostate cancer	0.000156	0.00261	CbGeAlD
Sorafenib—ABCG2—seminal vesicle—prostate cancer	0.00015	0.00251	CbGeAlD
Sorafenib—Regorafenib—CYP3A4—prostate cancer	0.000145	0.0503	CrCbGaD
Sorafenib—RALBP1—lymph node—prostate cancer	0.000144	0.00242	CbGeAlD
Sorafenib—KIT—testis—prostate cancer	0.000142	0.00238	CbGeAlD
Sorafenib—PDGFRB—testis—prostate cancer	0.000139	0.00232	CbGeAlD
Sorafenib—FLT1—lymph node—prostate cancer	0.000137	0.0023	CbGeAlD
Sorafenib—RAF1—lymph node—prostate cancer	0.000137	0.00229	CbGeAlD
Sorafenib—EPHB6—lymph node—prostate cancer	0.000136	0.00228	CbGeAlD
Sorafenib—STK10—lymph node—prostate cancer	0.00013	0.00218	CbGeAlD
Sorafenib—ABCC4—bone marrow—prostate cancer	0.000129	0.00216	CbGeAlD
Sorafenib—PDGFRA—lymph node—prostate cancer	0.000129	0.00216	CbGeAlD
Sorafenib—CYP2C8—renal system—prostate cancer	0.000124	0.00208	CbGeAlD
Sorafenib—CDK7—Idarubicin—Epirubicin—prostate cancer	0.000122	0.0618	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Epirubicin—prostate cancer	0.000122	0.0618	CbGdCrCtD
Sorafenib—CDK7—Doxorubicin—Epirubicin—prostate cancer	0.000122	0.0618	CbGdCrCtD
Sorafenib—ABCG2—urethra—prostate cancer	0.000118	0.00199	CbGeAlD
Sorafenib—MAP2K5—lymph node—prostate cancer	0.000116	0.00195	CbGeAlD
Sorafenib—KDR—lymph node—prostate cancer	0.000116	0.00195	CbGeAlD
Sorafenib—CYP1A2—renal system—prostate cancer	0.000116	0.00195	CbGeAlD
Sorafenib—Vismodegib—CYP3A4—prostate cancer	0.000115	0.0399	CrCbGaD
Sorafenib—CSF1R—lymph node—prostate cancer	0.000113	0.0019	CbGeAlD
Sorafenib—CDK7—Epirubicin—Doxorubicin—prostate cancer	0.000113	0.0571	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Doxorubicin—prostate cancer	0.000113	0.0571	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Doxorubicin—prostate cancer	0.000113	0.0571	CbGdCrCtD
Sorafenib—CYP3A5—renal system—prostate cancer	0.000112	0.00188	CbGeAlD
Sorafenib—CYP2B6—renal system—prostate cancer	0.000111	0.00186	CbGeAlD
Sorafenib—ABCC4—testis—prostate cancer	0.00011	0.00185	CbGeAlD
Sorafenib—ABCC2—testis—prostate cancer	0.000107	0.00179	CbGeAlD
Sorafenib—KIT—lymph node—prostate cancer	0.000103	0.00173	CbGeAlD
Sorafenib—PDGFRB—lymph node—prostate cancer	0.000101	0.00168	CbGeAlD
Sorafenib—ABCG2—bone marrow—prostate cancer	9.12e-05	0.00153	CbGeAlD
Sorafenib—ABCB1—prostate gland—prostate cancer	8.73e-05	0.00146	CbGeAlD
Sorafenib—CYP3A4—renal system—prostate cancer	8.4e-05	0.00141	CbGeAlD
Sorafenib—CYP2D6—renal system—prostate cancer	8.27e-05	0.00139	CbGeAlD
Sorafenib—CYP2C8—testis—prostate cancer	8.02e-05	0.00134	CbGeAlD
Sorafenib—ABCC4—lymph node—prostate cancer	8.01e-05	0.00134	CbGeAlD
Sorafenib—HTR2B—lymph node—prostate cancer	7.96e-05	0.00133	CbGeAlD
Sorafenib—ABCG2—testis—prostate cancer	7.8e-05	0.00131	CbGeAlD
Sorafenib—ABCC2—lymph node—prostate cancer	7.75e-05	0.0013	CbGeAlD
Sorafenib—ABCB1—seminal vesicle—prostate cancer	7.38e-05	0.00124	CbGeAlD
Sorafenib—CYP2B6—testis—prostate cancer	7.19e-05	0.00121	CbGeAlD
Sorafenib—ABCB1—epithelium—prostate cancer	6.41e-05	0.00107	CbGeAlD
Sorafenib—ABCB1—renal system—prostate cancer	5.95e-05	0.000997	CbGeAlD
Sorafenib—ABCB1—urethra—prostate cancer	5.84e-05	0.000979	CbGeAlD
Sorafenib—ABCG2—lymph node—prostate cancer	5.65e-05	0.000947	CbGeAlD
Sorafenib—CYP2D6—testis—prostate cancer	5.34e-05	0.000896	CbGeAlD
Sorafenib—ABCB1—bone marrow—prostate cancer	4.5e-05	0.000754	CbGeAlD
Sorafenib—ABCB1—testis—prostate cancer	3.84e-05	0.000644	CbGeAlD
Sorafenib—ABCB1—lymph node—prostate cancer	2.79e-05	0.000467	CbGeAlD
Sorafenib—Neutropenia—Doxorubicin—prostate cancer	2.46e-05	0.000214	CcSEcCtD
Sorafenib—Hypertension—Capecitabine—prostate cancer	2.46e-05	0.000214	CcSEcCtD
Sorafenib—Dry mouth—Docetaxel—prostate cancer	2.45e-05	0.000213	CcSEcCtD
Sorafenib—Arthralgia—Capecitabine—prostate cancer	2.42e-05	0.000211	CcSEcCtD
Sorafenib—Myalgia—Capecitabine—prostate cancer	2.42e-05	0.000211	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	2.41e-05	0.000209	CcSEcCtD
Sorafenib—Hepatobiliary disease—Epirubicin—prostate cancer	2.4e-05	0.000209	CcSEcCtD
Sorafenib—Anaphylactic shock—Docetaxel—prostate cancer	2.4e-05	0.000209	CcSEcCtD
Sorafenib—Epistaxis—Epirubicin—prostate cancer	2.39e-05	0.000208	CcSEcCtD
Sorafenib—Infection—Docetaxel—prostate cancer	2.38e-05	0.000207	CcSEcCtD
Sorafenib—Weight decreased—Doxorubicin—prostate cancer	2.38e-05	0.000207	CcSEcCtD
Sorafenib—Diarrhoea—Mitoxantrone—prostate cancer	2.38e-05	0.000207	CcSEcCtD
Sorafenib—Dry mouth—Capecitabine—prostate cancer	2.37e-05	0.000206	CcSEcCtD
Sorafenib—Vomiting—Estradiol—prostate cancer	2.37e-05	0.000206	CcSEcCtD
Sorafenib—Pneumonia—Doxorubicin—prostate cancer	2.36e-05	0.000205	CcSEcCtD
Sorafenib—Gastrointestinal pain—Etoposide—prostate cancer	2.36e-05	0.000205	CcSEcCtD
Sorafenib—Shock—Docetaxel—prostate cancer	2.36e-05	0.000205	CcSEcCtD
Sorafenib—Nervous system disorder—Docetaxel—prostate cancer	2.35e-05	0.000205	CcSEcCtD
Sorafenib—Thrombocytopenia—Docetaxel—prostate cancer	2.35e-05	0.000204	CcSEcCtD
Sorafenib—Rash—Estradiol—prostate cancer	2.35e-05	0.000204	CcSEcCtD
Sorafenib—Infestation NOS—Doxorubicin—prostate cancer	2.35e-05	0.000204	CcSEcCtD
Sorafenib—Infestation—Doxorubicin—prostate cancer	2.35e-05	0.000204	CcSEcCtD
Sorafenib—Dermatitis—Estradiol—prostate cancer	2.35e-05	0.000204	CcSEcCtD
Sorafenib—Anaemia—Prednisone—prostate cancer	2.34e-05	0.000204	CcSEcCtD
Sorafenib—Headache—Estradiol—prostate cancer	2.33e-05	0.000203	CcSEcCtD
Sorafenib—Skin disorder—Docetaxel—prostate cancer	2.33e-05	0.000203	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	2.33e-05	0.000202	CcSEcCtD
Sorafenib—Angioedema—Prednisone—prostate cancer	2.32e-05	0.000202	CcSEcCtD
Sorafenib—Renal failure—Doxorubicin—prostate cancer	2.31e-05	0.000201	CcSEcCtD
Sorafenib—Infection—Capecitabine—prostate cancer	2.31e-05	0.000201	CcSEcCtD
Sorafenib—Neuropathy peripheral—Doxorubicin—prostate cancer	2.3e-05	0.0002	CcSEcCtD
Sorafenib—Urticaria—Etoposide—prostate cancer	2.29e-05	0.000199	CcSEcCtD
Sorafenib—Haemoglobin—Epirubicin—prostate cancer	2.29e-05	0.000199	CcSEcCtD
Sorafenib—Stomatitis—Doxorubicin—prostate cancer	2.29e-05	0.000199	CcSEcCtD
Sorafenib—Jaundice—Doxorubicin—prostate cancer	2.29e-05	0.000199	CcSEcCtD
Sorafenib—Anorexia—Docetaxel—prostate cancer	2.29e-05	0.000199	CcSEcCtD
Sorafenib—Shock—Capecitabine—prostate cancer	2.29e-05	0.000199	CcSEcCtD
Sorafenib—Abdominal pain—Etoposide—prostate cancer	2.28e-05	0.000199	CcSEcCtD
Sorafenib—Body temperature increased—Etoposide—prostate cancer	2.28e-05	0.000199	CcSEcCtD
Sorafenib—Nervous system disorder—Capecitabine—prostate cancer	2.28e-05	0.000198	CcSEcCtD
Sorafenib—Haemorrhage—Epirubicin—prostate cancer	2.28e-05	0.000198	CcSEcCtD
Sorafenib—Thrombocytopenia—Capecitabine—prostate cancer	2.28e-05	0.000198	CcSEcCtD
Sorafenib—Syncope—Prednisone—prostate cancer	2.27e-05	0.000198	CcSEcCtD
Sorafenib—Skin disorder—Capecitabine—prostate cancer	2.26e-05	0.000196	CcSEcCtD
Sorafenib—Urinary tract disorder—Epirubicin—prostate cancer	2.25e-05	0.000196	CcSEcCtD
Sorafenib—Connective tissue disorder—Epirubicin—prostate cancer	2.24e-05	0.000195	CcSEcCtD
Sorafenib—Urethral disorder—Epirubicin—prostate cancer	2.23e-05	0.000194	CcSEcCtD
Sorafenib—Loss of consciousness—Prednisone—prostate cancer	2.23e-05	0.000194	CcSEcCtD
Sorafenib—Hepatobiliary disease—Doxorubicin—prostate cancer	2.22e-05	0.000193	CcSEcCtD
Sorafenib—Epistaxis—Doxorubicin—prostate cancer	2.22e-05	0.000193	CcSEcCtD
Sorafenib—Anorexia—Capecitabine—prostate cancer	2.22e-05	0.000193	CcSEcCtD
Sorafenib—Nausea—Estradiol—prostate cancer	2.21e-05	0.000192	CcSEcCtD
Sorafenib—Vomiting—Mitoxantrone—prostate cancer	2.21e-05	0.000192	CcSEcCtD
Sorafenib—Hypertension—Prednisone—prostate cancer	2.19e-05	0.00019	CcSEcCtD
Sorafenib—Rash—Mitoxantrone—prostate cancer	2.19e-05	0.00019	CcSEcCtD
Sorafenib—Dermatitis—Mitoxantrone—prostate cancer	2.19e-05	0.00019	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Docetaxel—prostate cancer	2.19e-05	0.00019	CcSEcCtD
Sorafenib—Headache—Mitoxantrone—prostate cancer	2.18e-05	0.000189	CcSEcCtD
Sorafenib—Arthralgia—Prednisone—prostate cancer	2.16e-05	0.000188	CcSEcCtD
Sorafenib—Myalgia—Prednisone—prostate cancer	2.16e-05	0.000188	CcSEcCtD
Sorafenib—Erythema multiforme—Epirubicin—prostate cancer	2.15e-05	0.000187	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2.14e-05	0.000186	CcSEcCtD
Sorafenib—Dyspnoea—Docetaxel—prostate cancer	2.14e-05	0.000186	CcSEcCtD
Sorafenib—Hypersensitivity—Etoposide—prostate cancer	2.13e-05	0.000185	CcSEcCtD
Sorafenib—Tinnitus—Epirubicin—prostate cancer	2.12e-05	0.000185	CcSEcCtD
Sorafenib—Haemoglobin—Doxorubicin—prostate cancer	2.12e-05	0.000184	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Capecitabine—prostate cancer	2.12e-05	0.000184	CcSEcCtD
Sorafenib—Cardiac disorder—Epirubicin—prostate cancer	2.12e-05	0.000184	CcSEcCtD
Sorafenib—Flushing—Epirubicin—prostate cancer	2.12e-05	0.000184	CcSEcCtD
Sorafenib—Dyspepsia—Docetaxel—prostate cancer	2.11e-05	0.000184	CcSEcCtD
Sorafenib—Haemorrhage—Doxorubicin—prostate cancer	2.11e-05	0.000183	CcSEcCtD
Sorafenib—Decreased appetite—Docetaxel—prostate cancer	2.09e-05	0.000181	CcSEcCtD
Sorafenib—Urinary tract disorder—Doxorubicin—prostate cancer	2.08e-05	0.000181	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Docetaxel—prostate cancer	2.07e-05	0.00018	CcSEcCtD
Sorafenib—Asthenia—Etoposide—prostate cancer	2.07e-05	0.00018	CcSEcCtD
Sorafenib—Connective tissue disorder—Doxorubicin—prostate cancer	2.07e-05	0.00018	CcSEcCtD
Sorafenib—Dyspnoea—Capecitabine—prostate cancer	2.07e-05	0.00018	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisone—prostate cancer	2.07e-05	0.00018	CcSEcCtD
Sorafenib—Fatigue—Docetaxel—prostate cancer	2.07e-05	0.00018	CcSEcCtD
Sorafenib—Angiopathy—Epirubicin—prostate cancer	2.07e-05	0.00018	CcSEcCtD
Sorafenib—Urethral disorder—Doxorubicin—prostate cancer	2.07e-05	0.00018	CcSEcCtD
Sorafenib—Nausea—Mitoxantrone—prostate cancer	2.06e-05	0.000179	CcSEcCtD
Sorafenib—Immune system disorder—Epirubicin—prostate cancer	2.06e-05	0.000179	CcSEcCtD
Sorafenib—Infection—Prednisone—prostate cancer	2.06e-05	0.000179	CcSEcCtD
Sorafenib—Mediastinal disorder—Epirubicin—prostate cancer	2.05e-05	0.000179	CcSEcCtD
Sorafenib—Pain—Docetaxel—prostate cancer	2.05e-05	0.000178	CcSEcCtD
Sorafenib—Constipation—Docetaxel—prostate cancer	2.05e-05	0.000178	CcSEcCtD
Sorafenib—Dyspepsia—Capecitabine—prostate cancer	2.05e-05	0.000178	CcSEcCtD
Sorafenib—Pruritus—Etoposide—prostate cancer	2.04e-05	0.000178	CcSEcCtD
Sorafenib—Shock—Prednisone—prostate cancer	2.04e-05	0.000177	CcSEcCtD
Sorafenib—Arrhythmia—Epirubicin—prostate cancer	2.04e-05	0.000177	CcSEcCtD
Sorafenib—Nervous system disorder—Prednisone—prostate cancer	2.03e-05	0.000177	CcSEcCtD
Sorafenib—Decreased appetite—Capecitabine—prostate cancer	2.02e-05	0.000176	CcSEcCtD
Sorafenib—Alopecia—Epirubicin—prostate cancer	2.01e-05	0.000175	CcSEcCtD
Sorafenib—Skin disorder—Prednisone—prostate cancer	2.01e-05	0.000175	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Capecitabine—prostate cancer	2.01e-05	0.000174	CcSEcCtD
Sorafenib—Fatigue—Capecitabine—prostate cancer	2e-05	0.000174	CcSEcCtD
Sorafenib—Mental disorder—Epirubicin—prostate cancer	2e-05	0.000174	CcSEcCtD
Sorafenib—Erythema multiforme—Doxorubicin—prostate cancer	1.99e-05	0.000173	CcSEcCtD
Sorafenib—Pain—Capecitabine—prostate cancer	1.99e-05	0.000173	CcSEcCtD
Sorafenib—Constipation—Capecitabine—prostate cancer	1.99e-05	0.000173	CcSEcCtD
Sorafenib—Malnutrition—Epirubicin—prostate cancer	1.98e-05	0.000172	CcSEcCtD
Sorafenib—Erythema—Epirubicin—prostate cancer	1.98e-05	0.000172	CcSEcCtD
Sorafenib—Diarrhoea—Etoposide—prostate cancer	1.98e-05	0.000172	CcSEcCtD
Sorafenib—Anorexia—Prednisone—prostate cancer	1.97e-05	0.000172	CcSEcCtD
Sorafenib—Tinnitus—Doxorubicin—prostate cancer	1.97e-05	0.000171	CcSEcCtD
Sorafenib—Gastrointestinal pain—Docetaxel—prostate cancer	1.96e-05	0.000171	CcSEcCtD
Sorafenib—Cardiac disorder—Doxorubicin—prostate cancer	1.96e-05	0.00017	CcSEcCtD
Sorafenib—Flushing—Doxorubicin—prostate cancer	1.96e-05	0.00017	CcSEcCtD
Sorafenib—Dysgeusia—Epirubicin—prostate cancer	1.94e-05	0.000169	CcSEcCtD
Sorafenib—Angiopathy—Doxorubicin—prostate cancer	1.91e-05	0.000166	CcSEcCtD
Sorafenib—Dizziness—Etoposide—prostate cancer	1.91e-05	0.000166	CcSEcCtD
Sorafenib—Muscle spasms—Epirubicin—prostate cancer	1.91e-05	0.000166	CcSEcCtD
Sorafenib—Immune system disorder—Doxorubicin—prostate cancer	1.9e-05	0.000166	CcSEcCtD
Sorafenib—Gastrointestinal pain—Capecitabine—prostate cancer	1.9e-05	0.000165	CcSEcCtD
Sorafenib—Mediastinal disorder—Doxorubicin—prostate cancer	1.9e-05	0.000165	CcSEcCtD
Sorafenib—Abdominal pain—Docetaxel—prostate cancer	1.9e-05	0.000165	CcSEcCtD
Sorafenib—Body temperature increased—Docetaxel—prostate cancer	1.9e-05	0.000165	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Prednisone—prostate cancer	1.89e-05	0.000164	CcSEcCtD
Sorafenib—Arrhythmia—Doxorubicin—prostate cancer	1.88e-05	0.000164	CcSEcCtD
Sorafenib—Alopecia—Doxorubicin—prostate cancer	1.86e-05	0.000162	CcSEcCtD
Sorafenib—Mental disorder—Doxorubicin—prostate cancer	1.85e-05	0.000161	CcSEcCtD
Sorafenib—Urticaria—Capecitabine—prostate cancer	1.85e-05	0.000161	CcSEcCtD
Sorafenib—Body temperature increased—Capecitabine—prostate cancer	1.84e-05	0.00016	CcSEcCtD
Sorafenib—Abdominal pain—Capecitabine—prostate cancer	1.84e-05	0.00016	CcSEcCtD
Sorafenib—Vomiting—Etoposide—prostate cancer	1.84e-05	0.00016	CcSEcCtD
Sorafenib—Erythema—Doxorubicin—prostate cancer	1.84e-05	0.00016	CcSEcCtD
Sorafenib—Malnutrition—Doxorubicin—prostate cancer	1.84e-05	0.00016	CcSEcCtD
Sorafenib—Anaemia—Epirubicin—prostate cancer	1.83e-05	0.000159	CcSEcCtD
Sorafenib—Dyspepsia—Prednisone—prostate cancer	1.82e-05	0.000158	CcSEcCtD
Sorafenib—Rash—Etoposide—prostate cancer	1.82e-05	0.000158	CcSEcCtD
Sorafenib—Dermatitis—Etoposide—prostate cancer	1.82e-05	0.000158	CcSEcCtD
Sorafenib—Headache—Etoposide—prostate cancer	1.81e-05	0.000157	CcSEcCtD
Sorafenib—Decreased appetite—Prednisone—prostate cancer	1.8e-05	0.000156	CcSEcCtD
Sorafenib—Dysgeusia—Doxorubicin—prostate cancer	1.8e-05	0.000156	CcSEcCtD
Sorafenib—Fatigue—Prednisone—prostate cancer	1.78e-05	0.000155	CcSEcCtD
Sorafenib—Syncope—Epirubicin—prostate cancer	1.78e-05	0.000155	CcSEcCtD
Sorafenib—Leukopenia—Epirubicin—prostate cancer	1.78e-05	0.000154	CcSEcCtD
Sorafenib—Constipation—Prednisone—prostate cancer	1.77e-05	0.000154	CcSEcCtD
Sorafenib—Hypersensitivity—Docetaxel—prostate cancer	1.77e-05	0.000154	CcSEcCtD
Sorafenib—Muscle spasms—Doxorubicin—prostate cancer	1.76e-05	0.000153	CcSEcCtD
Sorafenib—Loss of consciousness—Epirubicin—prostate cancer	1.74e-05	0.000152	CcSEcCtD
Sorafenib—Cough—Epirubicin—prostate cancer	1.73e-05	0.000151	CcSEcCtD
Sorafenib—Asthenia—Docetaxel—prostate cancer	1.72e-05	0.00015	CcSEcCtD
Sorafenib—Nausea—Etoposide—prostate cancer	1.72e-05	0.000149	CcSEcCtD
Sorafenib—Hypertension—Epirubicin—prostate cancer	1.71e-05	0.000149	CcSEcCtD
Sorafenib—Hypersensitivity—Capecitabine—prostate cancer	1.71e-05	0.000149	CcSEcCtD
Sorafenib—Pruritus—Docetaxel—prostate cancer	1.7e-05	0.000148	CcSEcCtD
Sorafenib—Anaemia—Doxorubicin—prostate cancer	1.7e-05	0.000148	CcSEcCtD
Sorafenib—Gastrointestinal pain—Prednisone—prostate cancer	1.69e-05	0.000147	CcSEcCtD
Sorafenib—Myalgia—Epirubicin—prostate cancer	1.69e-05	0.000147	CcSEcCtD
Sorafenib—Arthralgia—Epirubicin—prostate cancer	1.69e-05	0.000147	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.68e-05	0.000146	CcSEcCtD
Sorafenib—Asthenia—Capecitabine—prostate cancer	1.67e-05	0.000145	CcSEcCtD
Sorafenib—Dry mouth—Epirubicin—prostate cancer	1.65e-05	0.000144	CcSEcCtD
Sorafenib—Syncope—Doxorubicin—prostate cancer	1.65e-05	0.000143	CcSEcCtD
Sorafenib—Urticaria—Prednisone—prostate cancer	1.64e-05	0.000143	CcSEcCtD
Sorafenib—Pruritus—Capecitabine—prostate cancer	1.64e-05	0.000143	CcSEcCtD
Sorafenib—Leukopenia—Doxorubicin—prostate cancer	1.64e-05	0.000143	CcSEcCtD
Sorafenib—Diarrhoea—Docetaxel—prostate cancer	1.64e-05	0.000143	CcSEcCtD
Sorafenib—Abdominal pain—Prednisone—prostate cancer	1.64e-05	0.000142	CcSEcCtD
Sorafenib—Body temperature increased—Prednisone—prostate cancer	1.64e-05	0.000142	CcSEcCtD
Sorafenib—Anaphylactic shock—Epirubicin—prostate cancer	1.62e-05	0.000141	CcSEcCtD
Sorafenib—Loss of consciousness—Doxorubicin—prostate cancer	1.61e-05	0.00014	CcSEcCtD
Sorafenib—Infection—Epirubicin—prostate cancer	1.61e-05	0.00014	CcSEcCtD
Sorafenib—Cough—Doxorubicin—prostate cancer	1.6e-05	0.000139	CcSEcCtD
Sorafenib—Shock—Epirubicin—prostate cancer	1.59e-05	0.000138	CcSEcCtD
Sorafenib—Diarrhoea—Capecitabine—prostate cancer	1.59e-05	0.000138	CcSEcCtD
Sorafenib—Nervous system disorder—Epirubicin—prostate cancer	1.59e-05	0.000138	CcSEcCtD
Sorafenib—Dizziness—Docetaxel—prostate cancer	1.59e-05	0.000138	CcSEcCtD
Sorafenib—Thrombocytopenia—Epirubicin—prostate cancer	1.59e-05	0.000138	CcSEcCtD
Sorafenib—Hypertension—Doxorubicin—prostate cancer	1.58e-05	0.000138	CcSEcCtD
Sorafenib—Skin disorder—Epirubicin—prostate cancer	1.57e-05	0.000137	CcSEcCtD
Sorafenib—Myalgia—Doxorubicin—prostate cancer	1.56e-05	0.000136	CcSEcCtD
Sorafenib—Arthralgia—Doxorubicin—prostate cancer	1.56e-05	0.000136	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.55e-05	0.000135	CcSEcCtD
Sorafenib—Anorexia—Epirubicin—prostate cancer	1.54e-05	0.000134	CcSEcCtD
Sorafenib—Dizziness—Capecitabine—prostate cancer	1.54e-05	0.000134	CcSEcCtD
Sorafenib—Dry mouth—Doxorubicin—prostate cancer	1.53e-05	0.000133	CcSEcCtD
Sorafenib—Vomiting—Docetaxel—prostate cancer	1.53e-05	0.000133	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisone—prostate cancer	1.53e-05	0.000133	CcSEcCtD
Sorafenib—Rash—Docetaxel—prostate cancer	1.51e-05	0.000132	CcSEcCtD
Sorafenib—Dermatitis—Docetaxel—prostate cancer	1.51e-05	0.000131	CcSEcCtD
Sorafenib—Headache—Docetaxel—prostate cancer	1.5e-05	0.000131	CcSEcCtD
Sorafenib—Anaphylactic shock—Doxorubicin—prostate cancer	1.5e-05	0.00013	CcSEcCtD
Sorafenib—Infection—Doxorubicin—prostate cancer	1.49e-05	0.000129	CcSEcCtD
Sorafenib—Asthenia—Prednisone—prostate cancer	1.49e-05	0.000129	CcSEcCtD
Sorafenib—Vomiting—Capecitabine—prostate cancer	1.48e-05	0.000128	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.48e-05	0.000128	CcSEcCtD
Sorafenib—Shock—Doxorubicin—prostate cancer	1.47e-05	0.000128	CcSEcCtD
Sorafenib—Nervous system disorder—Doxorubicin—prostate cancer	1.47e-05	0.000128	CcSEcCtD
Sorafenib—Thrombocytopenia—Doxorubicin—prostate cancer	1.47e-05	0.000128	CcSEcCtD
Sorafenib—Rash—Capecitabine—prostate cancer	1.47e-05	0.000127	CcSEcCtD
Sorafenib—Pruritus—Prednisone—prostate cancer	1.46e-05	0.000127	CcSEcCtD
Sorafenib—Dermatitis—Capecitabine—prostate cancer	1.46e-05	0.000127	CcSEcCtD
Sorafenib—Headache—Capecitabine—prostate cancer	1.46e-05	0.000127	CcSEcCtD
Sorafenib—Skin disorder—Doxorubicin—prostate cancer	1.46e-05	0.000127	CcSEcCtD
Sorafenib—Dyspnoea—Epirubicin—prostate cancer	1.44e-05	0.000125	CcSEcCtD
Sorafenib—Anorexia—Doxorubicin—prostate cancer	1.43e-05	0.000124	CcSEcCtD
Sorafenib—Nausea—Docetaxel—prostate cancer	1.43e-05	0.000124	CcSEcCtD
Sorafenib—Dyspepsia—Epirubicin—prostate cancer	1.43e-05	0.000124	CcSEcCtD
Sorafenib—Diarrhoea—Prednisone—prostate cancer	1.42e-05	0.000123	CcSEcCtD
Sorafenib—Decreased appetite—Epirubicin—prostate cancer	1.41e-05	0.000122	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Epirubicin—prostate cancer	1.4e-05	0.000122	CcSEcCtD
Sorafenib—Fatigue—Epirubicin—prostate cancer	1.4e-05	0.000121	CcSEcCtD
Sorafenib—Constipation—Epirubicin—prostate cancer	1.38e-05	0.00012	CcSEcCtD
Sorafenib—Pain—Epirubicin—prostate cancer	1.38e-05	0.00012	CcSEcCtD
Sorafenib—Nausea—Capecitabine—prostate cancer	1.38e-05	0.00012	CcSEcCtD
Sorafenib—Dizziness—Prednisone—prostate cancer	1.37e-05	0.000119	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.36e-05	0.000119	CcSEcCtD
Sorafenib—Dyspnoea—Doxorubicin—prostate cancer	1.34e-05	0.000116	CcSEcCtD
Sorafenib—Gastrointestinal pain—Epirubicin—prostate cancer	1.32e-05	0.000115	CcSEcCtD
Sorafenib—Dyspepsia—Doxorubicin—prostate cancer	1.32e-05	0.000115	CcSEcCtD
Sorafenib—Vomiting—Prednisone—prostate cancer	1.32e-05	0.000114	CcSEcCtD
Sorafenib—Rash—Prednisone—prostate cancer	1.31e-05	0.000113	CcSEcCtD
Sorafenib—Dermatitis—Prednisone—prostate cancer	1.3e-05	0.000113	CcSEcCtD
Sorafenib—Decreased appetite—Doxorubicin—prostate cancer	1.3e-05	0.000113	CcSEcCtD
Sorafenib—Headache—Prednisone—prostate cancer	1.3e-05	0.000113	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.29e-05	0.000112	CcSEcCtD
Sorafenib—Fatigue—Doxorubicin—prostate cancer	1.29e-05	0.000112	CcSEcCtD
Sorafenib—Urticaria—Epirubicin—prostate cancer	1.29e-05	0.000112	CcSEcCtD
Sorafenib—Pain—Doxorubicin—prostate cancer	1.28e-05	0.000111	CcSEcCtD
Sorafenib—Constipation—Doxorubicin—prostate cancer	1.28e-05	0.000111	CcSEcCtD
Sorafenib—Body temperature increased—Epirubicin—prostate cancer	1.28e-05	0.000111	CcSEcCtD
Sorafenib—Abdominal pain—Epirubicin—prostate cancer	1.28e-05	0.000111	CcSEcCtD
Sorafenib—Nausea—Prednisone—prostate cancer	1.23e-05	0.000107	CcSEcCtD
Sorafenib—Gastrointestinal pain—Doxorubicin—prostate cancer	1.23e-05	0.000107	CcSEcCtD
Sorafenib—Hypersensitivity—Epirubicin—prostate cancer	1.19e-05	0.000104	CcSEcCtD
Sorafenib—Urticaria—Doxorubicin—prostate cancer	1.19e-05	0.000103	CcSEcCtD
Sorafenib—Abdominal pain—Doxorubicin—prostate cancer	1.18e-05	0.000103	CcSEcCtD
Sorafenib—Body temperature increased—Doxorubicin—prostate cancer	1.18e-05	0.000103	CcSEcCtD
Sorafenib—Asthenia—Epirubicin—prostate cancer	1.16e-05	0.000101	CcSEcCtD
Sorafenib—Pruritus—Epirubicin—prostate cancer	1.15e-05	9.96e-05	CcSEcCtD
Sorafenib—Diarrhoea—Epirubicin—prostate cancer	1.11e-05	9.63e-05	CcSEcCtD
Sorafenib—Hypersensitivity—Doxorubicin—prostate cancer	1.1e-05	9.6e-05	CcSEcCtD
Sorafenib—Asthenia—Doxorubicin—prostate cancer	1.07e-05	9.34e-05	CcSEcCtD
Sorafenib—Dizziness—Epirubicin—prostate cancer	1.07e-05	9.31e-05	CcSEcCtD
Sorafenib—Pruritus—Doxorubicin—prostate cancer	1.06e-05	9.21e-05	CcSEcCtD
Sorafenib—Vomiting—Epirubicin—prostate cancer	1.03e-05	8.95e-05	CcSEcCtD
Sorafenib—Diarrhoea—Doxorubicin—prostate cancer	1.03e-05	8.91e-05	CcSEcCtD
Sorafenib—Rash—Epirubicin—prostate cancer	1.02e-05	8.88e-05	CcSEcCtD
Sorafenib—Dermatitis—Epirubicin—prostate cancer	1.02e-05	8.87e-05	CcSEcCtD
Sorafenib—Headache—Epirubicin—prostate cancer	1.01e-05	8.82e-05	CcSEcCtD
Sorafenib—Dizziness—Doxorubicin—prostate cancer	9.91e-06	8.61e-05	CcSEcCtD
Sorafenib—Nausea—Epirubicin—prostate cancer	9.62e-06	8.36e-05	CcSEcCtD
Sorafenib—Vomiting—Doxorubicin—prostate cancer	9.53e-06	8.28e-05	CcSEcCtD
Sorafenib—Rash—Doxorubicin—prostate cancer	9.45e-06	8.21e-05	CcSEcCtD
Sorafenib—Dermatitis—Doxorubicin—prostate cancer	9.44e-06	8.2e-05	CcSEcCtD
Sorafenib—Headache—Doxorubicin—prostate cancer	9.39e-06	8.16e-05	CcSEcCtD
Sorafenib—Nausea—Doxorubicin—prostate cancer	8.9e-06	7.74e-05	CcSEcCtD
Sorafenib—ABCB1—Metabolism—MTHFR—prostate cancer	3.25e-07	2.77e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—prostate cancer	3.25e-07	2.77e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EGFR—prostate cancer	3.24e-07	2.77e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ERBB2—prostate cancer	3.24e-07	2.77e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.24e-07	2.77e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—prostate cancer	3.24e-07	2.76e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—prostate cancer	3.24e-07	2.76e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ERCC2—prostate cancer	3.23e-07	2.76e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—PIK3CA—prostate cancer	3.23e-07	2.76e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—prostate cancer	3.22e-07	2.75e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—prostate cancer	3.22e-07	2.75e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STAT3—prostate cancer	3.22e-07	2.75e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1A—prostate cancer	3.21e-07	2.74e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—COMT—prostate cancer	3.21e-07	2.74e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—prostate cancer	3.21e-07	2.74e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NCOA2—prostate cancer	3.21e-07	2.74e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—prostate cancer	3.21e-07	2.74e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTEN—prostate cancer	3.21e-07	2.74e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CB—prostate cancer	3.2e-07	2.73e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTP1—prostate cancer	3.19e-07	2.73e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—prostate cancer	3.19e-07	2.73e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—EP300—prostate cancer	3.19e-07	2.72e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARA—prostate cancer	3.19e-07	2.72e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CD—prostate cancer	3.18e-07	2.72e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—SRC—prostate cancer	3.18e-07	2.72e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—prostate cancer	3.16e-07	2.7e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—EP300—prostate cancer	3.16e-07	2.7e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ITPR1—prostate cancer	3.14e-07	2.68e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—prostate cancer	3.13e-07	2.68e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CG—prostate cancer	3.13e-07	2.68e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—prostate cancer	3.13e-07	2.67e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—prostate cancer	3.1e-07	2.65e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—prostate cancer	3.1e-07	2.64e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.09e-07	2.64e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—prostate cancer	3.08e-07	2.63e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—prostate cancer	3.07e-07	2.62e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—prostate cancer	3.07e-07	2.62e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CAV1—prostate cancer	3.07e-07	2.62e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STAT3—prostate cancer	3.07e-07	2.62e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—prostate cancer	3.07e-07	2.62e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—prostate cancer	3.06e-07	2.61e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC5A5—prostate cancer	3.06e-07	2.61e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EP300—prostate cancer	3.06e-07	2.61e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—prostate cancer	3.04e-07	2.59e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1B—prostate cancer	3e-07	2.57e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARA—prostate cancer	3e-07	2.57e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—prostate cancer	3e-07	2.56e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CAV1—prostate cancer	3e-07	2.56e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.99e-07	2.55e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—prostate cancer	2.99e-07	2.55e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—prostate cancer	2.98e-07	2.55e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARA—prostate cancer	2.98e-07	2.54e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PIK3CA—prostate cancer	2.97e-07	2.54e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PIK3CA—prostate cancer	2.97e-07	2.54e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—SRC—prostate cancer	2.97e-07	2.54e-06	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—prostate cancer	2.97e-07	2.54e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TYMS—prostate cancer	2.97e-07	2.54e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—INS—prostate cancer	2.97e-07	2.53e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—prostate cancer	2.96e-07	2.53e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NQO1—prostate cancer	2.96e-07	2.52e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CASP3—prostate cancer	2.95e-07	2.51e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—prostate cancer	2.94e-07	2.51e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTM1—prostate cancer	2.94e-07	2.51e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.93e-07	2.51e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—prostate cancer	2.93e-07	2.5e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EGFR—prostate cancer	2.92e-07	2.5e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—prostate cancer	2.92e-07	2.49e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TH—prostate cancer	2.91e-07	2.49e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CREBBP—prostate cancer	2.91e-07	2.48e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—prostate cancer	2.9e-07	2.47e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—prostate cancer	2.89e-07	2.47e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—LPL—prostate cancer	2.88e-07	2.46e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—prostate cancer	2.88e-07	2.46e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—prostate cancer	2.88e-07	2.46e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—prostate cancer	2.87e-07	2.45e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STAT3—prostate cancer	2.87e-07	2.45e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—prostate cancer	2.86e-07	2.44e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—prostate cancer	2.86e-07	2.44e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—prostate cancer	2.85e-07	2.43e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—prostate cancer	2.84e-07	2.43e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CTNNB1—prostate cancer	2.84e-07	2.42e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CB—prostate cancer	2.84e-07	2.42e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.83e-07	2.42e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CAV1—prostate cancer	2.82e-07	2.41e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PIK3CA—prostate cancer	2.82e-07	2.41e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PIK3CA—prostate cancer	2.82e-07	2.4e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—prostate cancer	2.81e-07	2.4e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CAV1—prostate cancer	2.8e-07	2.39e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CG—prostate cancer	2.8e-07	2.39e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EGFR—prostate cancer	2.79e-07	2.38e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—prostate cancer	2.78e-07	2.38e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP1A1—prostate cancer	2.78e-07	2.38e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3CA—prostate cancer	2.78e-07	2.37e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3CA—prostate cancer	2.78e-07	2.37e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1A—prostate cancer	2.77e-07	2.37e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CB—prostate cancer	2.77e-07	2.37e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTEN—prostate cancer	2.77e-07	2.36e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—prostate cancer	2.76e-07	2.36e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ERCC2—prostate cancer	2.76e-07	2.36e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CD—prostate cancer	2.75e-07	2.35e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—prostate cancer	2.75e-07	2.35e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GGT1—prostate cancer	2.74e-07	2.34e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—prostate cancer	2.73e-07	2.33e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CG—prostate cancer	2.73e-07	2.33e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—prostate cancer	2.72e-07	2.33e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NCOA1—prostate cancer	2.7e-07	2.31e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—prostate cancer	2.7e-07	2.3e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—prostate cancer	2.7e-07	2.3e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.68e-07	2.28e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—prostate cancer	2.67e-07	2.28e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.66e-07	2.27e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—prostate cancer	2.66e-07	2.27e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—prostate cancer	2.66e-07	2.27e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—INS—prostate cancer	2.65e-07	2.26e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EP300—prostate cancer	2.64e-07	2.25e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—prostate cancer	2.64e-07	2.25e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—prostate cancer	2.63e-07	2.25e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—prostate cancer	2.63e-07	2.25e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—prostate cancer	2.63e-07	2.25e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EGFR—prostate cancer	2.61e-07	2.22e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—prostate cancer	2.6e-07	2.22e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—prostate cancer	2.59e-07	2.22e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CREBBP—prostate cancer	2.59e-07	2.21e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—INS—prostate cancer	2.58e-07	2.21e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CG—prostate cancer	2.57e-07	2.2e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—RXRA—prostate cancer	2.57e-07	2.2e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SRC—prostate cancer	2.57e-07	2.19e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CG—prostate cancer	2.55e-07	2.18e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARA—prostate cancer	2.54e-07	2.17e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PIK3CA—prostate cancer	2.54e-07	2.17e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CREBBP—prostate cancer	2.53e-07	2.16e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—prostate cancer	2.5e-07	2.13e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—prostate cancer	2.5e-07	2.13e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—prostate cancer	2.49e-07	2.13e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—COMT—prostate cancer	2.48e-07	2.11e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STAT3—prostate cancer	2.47e-07	2.11e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTP1—prostate cancer	2.47e-07	2.1e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—prostate cancer	2.46e-07	2.1e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CD—prostate cancer	2.46e-07	2.1e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—prostate cancer	2.45e-07	2.1e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTEN—prostate cancer	2.45e-07	2.09e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—INS—prostate cancer	2.44e-07	2.08e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—prostate cancer	2.43e-07	2.08e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—prostate cancer	2.43e-07	2.08e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ITPR1—prostate cancer	2.43e-07	2.07e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PIK3CA—prostate cancer	2.42e-07	2.07e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—INS—prostate cancer	2.41e-07	2.06e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CB—prostate cancer	2.4e-07	2.05e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CD—prostate cancer	2.4e-07	2.05e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTEN—prostate cancer	2.4e-07	2.05e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CAV1—prostate cancer	2.39e-07	2.04e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CREBBP—prostate cancer	2.39e-07	2.04e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—prostate cancer	2.38e-07	2.03e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CREBBP—prostate cancer	2.36e-07	2.02e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3CA—prostate cancer	2.36e-07	2.01e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—prostate cancer	2.34e-07	2e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3CA—prostate cancer	2.34e-07	2e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—EP300—prostate cancer	2.34e-07	2e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—prostate cancer	2.32e-07	1.98e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—prostate cancer	2.31e-07	1.97e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—prostate cancer	2.3e-07	1.96e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—prostate cancer	2.3e-07	1.96e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—prostate cancer	2.29e-07	1.96e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TYMS—prostate cancer	2.29e-07	1.96e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.29e-07	1.95e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—EP300—prostate cancer	2.28e-07	1.95e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—prostate cancer	2.27e-07	1.94e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—prostate cancer	2.27e-07	1.94e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—prostate cancer	2.27e-07	1.94e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTM1—prostate cancer	2.27e-07	1.93e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CD—prostate cancer	2.26e-07	1.93e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PIK3CA—prostate cancer	2.26e-07	1.93e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EGFR—prostate cancer	2.25e-07	1.92e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—prostate cancer	2.25e-07	1.92e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CD—prostate cancer	2.24e-07	1.91e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—LPL—prostate cancer	2.22e-07	1.9e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—prostate cancer	2.19e-07	1.87e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CG—prostate cancer	2.18e-07	1.86e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.15e-07	1.83e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CB—prostate cancer	2.14e-07	1.83e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—prostate cancer	2.14e-07	1.83e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—prostate cancer	2.14e-07	1.82e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ERCC2—prostate cancer	2.13e-07	1.82e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—prostate cancer	2.12e-07	1.81e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—prostate cancer	2.12e-07	1.81e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—prostate cancer	2.12e-07	1.81e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CB—prostate cancer	2.09e-07	1.79e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTEN—prostate cancer	2.07e-07	1.77e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—prostate cancer	2.07e-07	1.77e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—prostate cancer	2.07e-07	1.77e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—INS—prostate cancer	2.06e-07	1.76e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CREBBP—prostate cancer	2.02e-07	1.73e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—prostate cancer	2e-07	1.71e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—prostate cancer	2e-07	1.71e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—EP300—prostate cancer	1.98e-07	1.69e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—prostate cancer	1.98e-07	1.69e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.97e-07	1.68e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARA—prostate cancer	1.96e-07	1.68e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CB—prostate cancer	1.95e-07	1.67e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—prostate cancer	1.95e-07	1.67e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	1.95e-07	1.67e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—prostate cancer	1.94e-07	1.65e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—prostate cancer	1.93e-07	1.65e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CD—prostate cancer	1.92e-07	1.64e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—prostate cancer	1.91e-07	1.63e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—prostate cancer	1.89e-07	1.61e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTEN—prostate cancer	1.85e-07	1.58e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—prostate cancer	1.85e-07	1.58e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CAV1—prostate cancer	1.85e-07	1.58e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—prostate cancer	1.81e-07	1.54e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTEN—prostate cancer	1.81e-07	1.54e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—EP300—prostate cancer	1.77e-07	1.51e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CA—prostate cancer	1.73e-07	1.48e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—prostate cancer	1.73e-07	1.48e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—EP300—prostate cancer	1.72e-07	1.47e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTEN—prostate cancer	1.7e-07	1.45e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CA—prostate cancer	1.69e-07	1.44e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTEN—prostate cancer	1.69e-07	1.44e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.68e-07	1.44e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CB—prostate cancer	1.67e-07	1.43e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—prostate cancer	1.65e-07	1.41e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—EP300—prostate cancer	1.62e-07	1.39e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—EP300—prostate cancer	1.61e-07	1.38e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—prostate cancer	1.59e-07	1.36e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—INS—prostate cancer	1.59e-07	1.36e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CREBBP—prostate cancer	1.56e-07	1.33e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.48e-07	1.26e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CA—prostate cancer	1.46e-07	1.25e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTEN—prostate cancer	1.44e-07	1.23e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—prostate cancer	1.41e-07	1.21e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—prostate cancer	1.4e-07	1.19e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—prostate cancer	1.38e-07	1.18e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—EP300—prostate cancer	1.38e-07	1.18e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CA—prostate cancer	1.31e-07	1.12e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.29e-07	1.1e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—prostate cancer	1.28e-07	1.09e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CA—prostate cancer	1.28e-07	1.09e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.2e-07	1.03e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—prostate cancer	1.2e-07	1.02e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CA—prostate cancer	1.19e-07	1.02e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTEN—prostate cancer	1.11e-07	9.51e-07	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—prostate cancer	1.07e-07	9.11e-07	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—EP300—prostate cancer	1.06e-07	9.07e-07	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—prostate cancer	1.04e-07	8.9e-07	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CA—prostate cancer	1.02e-07	8.69e-07	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—prostate cancer	9.82e-08	8.38e-07	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—prostate cancer	9.73e-08	8.31e-07	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—prostate cancer	8.32e-08	7.1e-07	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CA—prostate cancer	7.86e-08	6.71e-07	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—prostate cancer	6.42e-08	5.48e-07	CbGpPWpGaD
